| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Veterans Affairs Palo Alto Health Care System and Stanford University (A.R.H.), Palo Alto, California 94304; Medical Affairs (J.E.K., J.B.), Genentech, Inc., South San Francisco, California 94080; Harvard Medical School and Massachusetts General Hospital (H.B.A.B., B.M.K.B., A.K.), Boston, Massachusetts 02114; Duke University Medical Center (R.V.C.), Durham, North Carolina, 27710; Northwestern University Medical School (G.P.B.), Chicago, Illinois 60611; Oregon Health Sciences University (D.C.), Portland, Oregon 97201; Yale School of Medicine (S.E.I.), New Haven, Connecticut 06520; New York University Medical Center and Veterans Affairs Medical Center (D.K.), New York, New York 10010; Emory University School of Medicine (L.S.P.), Atlanta, Georgia 30322; University of Colorado Health Science Center (E.C.R.), Denver, Colorado 80220; Memorial Sloan-Kettering Cancer Center (R.J.R.), New York, New York 10021; University of Iowa (J.S.), Iowa City, Iowa 52242; George Washington University School of Medicine and Health Science (M.S.), Washington, D.C. 20037; and University of Virginia Health Science Center (M.O.T., M.L.V.), Charlottesville, Virginia 22908
Address all correspondence and requests for reprints to: Andrew R. Hoffman, M.D., Medical Service, VA Palo Alto Health Care System, 3801 Miranda Avenue, Palo Alto, California 94304. E-mail: arhoffman{at}stanford.edu.
Adult GH deficiency (AGHD) is characterized by an altered body composition, an atherogenic lipid profile, decreased exercise capacity, and diminished quality of life. We performed a randomized, double-blind, placebo-controlled, multicenter study in 166 subjects with AGHD to assess the effects of GH on these outcomes. GH was initiated at 0.0125 mg/kg·d, increased to 0.025 mg/kg·d as tolerated, or decreased to 0.00625 mg/kg·d for 12 months. Primary measures of efficacy included body composition, strength and endurance, and quality of life. Additional parameters included serum IGF-I concentrations, serum lipids, and bone mineral density.
After 12 months, 79% of subjects remained on GH 0.0125 mg/kg·d, whereas 21% received 0.00625 mg/kg·d. GH-treated men and women demonstrated significant decreases in total body and trunk fat and increases in lean body mass over baseline. In GH-treated men, mean IGF-I SD scores exceeded age-adjusted normal ranges, whereas similar doses produced a smaller response in women. GH treatment was associated with significant improvements in total cholesterol and low-density lipoprotein (P < 0.05 for all). No significant treatment effects were observed in strength and endurance, quality of life, or bone mineral density. GH treatment was generally well tolerated. Subjects with AGHD should receive individualized GH therapy to maintain IGF-I between the mean value and +2 SD and improve body composition and cardiovascular risk factors.
This work was supported by Genentech, Inc.
Abbreviations: AGHD, Adult GH deficiency; BMD, bone mineral density; BMI, body mass index; DXA, dual-energy x-ray absorptiometry; ERT, estrogen replacement therapy; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SDS, SD score.
This article has been cited by other articles:
 |
|
 |
|
  C Joaquin, E Aguilera, M L Granada, M C Pastor, I Salinas, N Alonso, and A Sanmarti Effects of GH treatment in GH-deficient adults on adiponectin, leptin and pregnancy-associated plasma protein-A. Eur. J. Endocrinol., April 1, 2008; 158(4): 483 - 490. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. M. Oliveira, M. H. Aguiar-Oliveira, A. D'Oliveira Jr, R. M. C. Pereira, C. R. P. Oliveira, C. T. Farias, J. A. Barreto-Filho, F. D. Anjos-Andrade, C. Marques-Santos, A. C. Nascimento-Junior, et al. Congenital Growth Hormone (GH) Deficiency and Atherosclerosis: Effects of GH Replacement in GH-Naive Adults J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4664 - 4670. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Keller, Z. Wu, J. Kratzsch, E. Keller, W. F Blum, A. Kniess, R. Preiss, J. Teichert, C. J Strasburger, and M. Bidlingmaier Pharmacokinetics and pharmacodynamics of GH: dependence on route and dosage of administration Eur. J. Endocrinol., June 1, 2007; 156(6): 647 - 653. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Bray and F. L. Greenway Pharmacological Treatment of the Overweight Patient Pharmacol. Rev., June 1, 2007; 59(2): 151 - 184. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Liu, D. M. Bravata, I. Olkin, S. Nayak, B. Roberts, A. M. Garber, and A. R. Hoffman Systematic Review: The Safety and Efficacy of Growth Hormone in the Healthy Elderly Ann Intern Med, January 16, 2007; 146(2): 104 - 115. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A M Solomon and P M G Bouloux Modifying muscle mass - the endocrine perspective. J. Endocrinol., November 1, 2006; 191(2): 349 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Abs, U. Feldt-Rasmussen, A. F Mattsson, J. P Monson, B.-A. Bengtsson, M. I Goth, P. Wilton, and M. Koltowska-Haggstrom Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults - a KIMS database analysis. Eur. J. Endocrinol., July 1, 2006; 155(1): 79 - 90. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Saller, A. F Mattsson, P. H Kann, H. P Koppeschaar, J. Svensson, M. Pompen, and M. Koltowska-Haggstrom Healthcare utilization, quality of life and patient-reported outcomes during two years of GH replacement therapy in GH-deficient adults - comparison between Sweden, The Netherlands and Germany. Eur. J. Endocrinol., June 1, 2006; 154(6): 843 - 850. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Menezes Oliveira, C. Marques-Santos, J. A. Barreto-Filho, R. Ximenes Filho, A. V. de Oliveira Britto, A. H. Oliveira Souza, C. M. Prado, C. R. Pereira Oliveira, R. M. C. Pereira, T. de Almeida Ribeiro Vicente, et al. Lack of Evidence of Premature Atherosclerosis in Untreated Severe Isolated Growth Hormone (GH) Deficiency due to a GH-Releasing Hormone Receptor Mutation J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2093 - 2099. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Sotiropoulos, M. Ohanna, C. Kedzia, R. K. Menon, J. J. Kopchick, P. A. Kelly, and M. Pende Growth hormone promotes skeletal muscle cell fusion independent of insulin-like growth factor 1 up-regulation PNAS, May 9, 2006; 103(19): 7315 - 7320. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Woodhouse, A. Mukherjee, S. M. Shalet, and S. Ezzat The Influence of Growth Hormone Status on Physical Impairments, Functional Limitations, and Health-Related Quality of Life in Adults Endocr. Rev., May 1, 2006; 27(3): 287 - 317. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Molitch, D. R. Clemmons, S. Malozowski, G. R. Merriam, S. M. Shalet, M. L. Vance, and for The Endocrine Society's Clinical Guidelines Su Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline J. Clin. Endocrinol. Metab., May 1, 2006; 91(5): 1621 - 1634. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Hoffman, B. M. K. Biller, D. Cook, J. Baptista, B. L. Silverman, L. Dao, K. M. Attie, P. Fielder, T. Maneatis, B. Lippe, et al. Efficacy of a Long-Acting Growth Hormone (GH) Preparation in Patients with Adult GH Deficiency J. Clin. Endocrinol. Metab., December 1, 2005; 90(12): 6431 - 6440. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Bollerslev, J. Hallen, K. J Fougner, A. P. Jorgensen, C. Kristo, H. Fagertun, O. Gudmundsen, P. Burman, and T. Schreiner Low-dose GH improves exercise capacity in adults with GH deficiency: effects of a 22-month placebo-controlled, crossover trial Eur. J. Endocrinol., September 1, 2005; 153(3): 379 - 387. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Lanes, A. Soros, K. Flores, P. Gunczler, E. Carrillo, and J. Bandel Endothelial Function, Carotid Artery Intima-Media Thickness, Epicardial Adipose Tissue, and Left Ventricular Mass and Function in Growth Hormone-Deficient Adolescents: Apparent Effects of Growth Hormone Treatment on These Parameters J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 3978 - 3982. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Misra, K. K. Miller, C. Almazan, M. Worley, D. B. Herzog, and A. Klibanski Hormonal Determinants of Regional Body Composition in Adolescent Girls with Anorexia Nervosa and Controls J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2580 - 2587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gola, S. Bonadonna, M. Doga, and A. Giustina Growth Hormone and Cardiovascular Risk Factors J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1864 - 1870. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
